Therapeutic Response

PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Cisplatin in combination with Fluorouracil and Pembrolizumab in patients with Head and Neck Squamous Cell Carcinoma.

Statements

Source and description
Keytruda (pembrolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.
Pembrolizumab, Cisplatin and 5-Fluorouracil Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with cisplatin and 5-fluorouracil for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a CPS >= 1.